Williams Cancer Institute

Menu
Menu
Uterine cancer (endometrial) · Interventional immuno-oncology

Endometrial cancer isn’t one disease. Our approach is tuned to yours.

For uterine cancer that has come back or spread — a needle-based treatment tuned to the specific biology of your tumor, when standard drugs fall short.

Personalized

Minimally invasive

Immune-activating

Outpatient

In plain terms

What we do, in three paragraphs.

Endometrial (uterine) cancer is no longer treated as one disease — it has several molecular subtypes with very different biology, and our approach is tuned to that. We treat the tumor directly: ablation plus intratumoral immunotherapy, often using PEF to treat pelvic disease without harming nearby bladder or bowel.
The two broad situations call for different tactics. dMMR / MSI-high tumors respond well to dostarlimab (Jemperli) — but once they stop responding, the problem is immune “exhaustion,” and we inject stimulants like CpG and OX40/CD40 agonists to re-energize fresh immune cells. pMMR tumors are “cold”; breaking the tumor open turns it “hot” and the injected immunotherapy converts it locally — AblationVax, aiming for the abscopal effect.
It’s designed for recurrent or metastatic disease progressing after dostarlimab (dMMR) or lenvatinib + pembrolizumab (pMMR), HER2-positive serous disease after targeted therapy, POLE-mutant disease, or a few growing spots. We coordinate with your gynecologic-oncology team; most patients finish in about a week. Results vary.

One needle, one session: ablation plus immunotherapy delivered where the cancer lives.

AblationVax: the treated tumor teaches your immune system to attack cancer body-wide.

Real outcomes

dMMR after Jemperli + pMMR through lenvatinib + pembrolizumab.

After progression on standard immune-active regimens, options narrow. Our approach: re-engage immunity at the tumor site, tuned to each molecular subtype.

Individual results vary. These outcomes represent specific patient cases and are not guaranteed for all patients.

Where our approach fits

Treatment options by stage.

Find your diagnosis below to see what standard care offers, where we add to it, and what role our approach plays.

Early (stage I–II)

Standard care
Hysterectomy ± adjuvant therapy.
What we add
Our approach is rarely first-line.
Standard care first

Locally advanced (III)

Standard care
Chemoradiation ± dostarlimab.
What we add
Selected adjunctive intratumoral immune priming.
Adjunct to standard care

Our primary focus

Recurrent / metastatic dMMR

Standard care
Chemo + dostarlimab (NRG-GY018 / RUBY).
What we add
Re-engagement after Jemperli progression.

After dostarlimab the issue is exhaustion, not antigenicity — intratumoral OX40 / CD40 + CpG amplifies fresh effector responses.

Systemic immune activation

Recurrent / metastatic pMMR

Standard care
Chemo + IO combinations; lenvatinib + pembrolizumab.
What we add
Ablation + intratumoral re-engagement for cold disease.
Cold-tumor activation

Beyond ablation alone

Destroy the tumor, then teach your immune system to finish the job.

Standard approaches
Our approach — AblationVax
dMMR: chemo + dostarlimab. pMMR: chemo + IO; lenvatinib + pembrolizumab.
Ablation + intratumoral immunotherapy after progression on standard immune-active regimens.

IV checkpoint blockade: standard systemic exposure.
Delivered directly into the tumor rather than through the bloodstream. The aim is to concentrate treatment at the tumor site and limit whole-body exposure.

Limited options after dostarlimab / lenva-pembro failure.
Multi-agent intratumoral cocktails as next-line consideration.

Why this approach for uterine cancer?

Treats tumors near critical structures

Pelvic anatomy, bladder, rectum, ureters — non-thermal PEF enables treatment where thermal ablation risks injury.

Converts “cold” tumors into “hot” targets

pMMR disease is cold; dMMR is warm-but-exhausted. Ablation + intratumoral immunotherapy addresses both.

Aims for systemic response

The investigational goal is to determine whether treating one tumor can stimulate immune activity at untreated sites elsewhere in the body.

Uterine-specific breakthrough

Molecular-subtype-aware intratumoral cocktails.

“Endometrial cancer is no longer one disease. POLE-mutant, MSI-H / dMMR, copy-number-low, and copy-number-high subtypes have very different immune biology — our intratumoral approach is tuned to each.”

— Dr. Jason R. Williams

dMMR / MSI-H re-engagement

These tumors generate abundant neoantigens; after dostarlimab, exhaustion is the issue. Intratumoral OX40 / CD40 + CpG re-energizes fresh effector responses.

pMMR cold-tumor conversion

Copy-number-high disease is colder — ablation + intratumoral immunotherapy converts the microenvironment locally from cold to hot.

HER2 / TROP-2 / FRα co-targeting

HER2+ uterine serous responds to trastuzumab; intratumoral immune amplification is a rational priming strategy alongside these targeted lines.

“Endometrial cancer is where molecular classification has reshaped treatment more than any other gynecologic malignancy. Intratumoral immunotherapy should be tuned to each subtype.” — Dr. Williams

Beyond the procedure: whole-patient support.

We optimize your entire system for the best possible response — and coordinate with the team you already have.

Gut microbiome optimization

Diet, probiotics, and related therapies to support a stronger immunotherapy response.

Off-label protocols

Strategic use of repurposed medications to enhance immune response.

Personalized cocktails

Multi-agent immunotherapy tailored to your specific cancer.

Oncologist coordination

We work alongside your current chemo and radiation team.

What to expect

Your path to treatment.

1

Case review

We review your pelvic MRI, PET-CT, and biomarker reports (MMR/MSI, p53, POLE, HER2, ER/PR).

2

Protocol design

A personalized cocktail tuned to molecular subtype and prior lines.

3

Procedure week

Image-guided PEF or cryoablation + intratumoral immunotherapy. Outpatient.

4

Follow-up

Imaging at 6–8 weeks, coordination with your home team.

Procedure ~1 hour

Recovery ~2 hours

All outpatient

Is this right for you?

You may be a candidate if:

✓Recurrent / metastatic disease progressing on dostarlimab (dMMR) or lenvatinib + pembrolizumab (pMMR)
✓HER2+ uterine serous progressing on trastuzumab regimens
✓POLE-mutant disease with progression
✓Oligoprogressive disease on systemic therapy

It may not be suitable if:

—Pelvic obstruction without a management plan
—Active severe infection
—Uncorrectable bleeding disorders
—Very poor performance status (ECOG ≥ 3)

Each case is individually evaluated by Dr. Williams’ team.

Track record

Innovation for uterine cancer.

2014

Multi-agent intratumoral protocols

The AblationVax concept.

2015

Combination protocols reported

Yervoy / Opdivo / CpG / PV-10 combinations.

Now

PEF + multi-agent intratumoral protocols

For dMMR and pMMR endometrial cancer.

Ready to move forward?

There is more ahead. Take the next step with confidence.

Complimentary evaluation.

Dr. Williams’ team will personally review your case and imaging — no cost, no obligation.

Or email info@williamscancerinstitute.com

Beverly Hills · San Jose del Cabo · Mexico City — most patients complete treatment in one week

(theme footer continues — owned by Astra)

Menu

Email Signup